Stocks and Investing
Stocks and Investing
Thu, August 20, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mohit Bansal Downgraded (BMRN) to Hold and Decreased Target to $86 on, Aug 20th, 2020
Mohit Bansal of Citigroup, Downgraded "BioMarin Pharmaceutical Inc." (BMRN) to Hold and Decreased Target from $148 to $86 on, Aug 20th, 2020.
Mohit has made no other calls on BMRN in the last 4 months.
There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 3 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $100 on, Wednesday, August 19th, 2020
- George Farmer of "BMO Capital" Maintained at Hold with Increased Target to $108 on, Thursday, August 6th, 2020
- Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $125 on, Wednesday, July 8th, 2020
This is the rating of the analyst that currently disagrees with Mohit
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $113 on, Wednesday, August 19th, 2020